1. Generics Bulletin
  3. >>Earnings

Viatris Slashes Full-Year Revenue Guidance By $800m

Strengthening US Dollar Continues To Be Significant Headwind

 
• By Dean Rudge

Viatris is committing to earlier EBITDA and free cash flow targets for 2022, although it now expects to lose a chunk of revenues for the full year amid severe and sustained foreign currency exposure.

Arrows down (Zoonar GmbH/Alamy Stock Photo)
Viatris is looking to launch lenalidomide in 2022 • Source: Shutterstock (Zoonar GmbH / Alamy Stock Photo/Alamy Stock Photo)

With the US dollar “strengthening significantly” against major global currencies, Viatris has slashed its full-year revenue guidance for 2022 by $800m.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Earnings

More from Business

What’s Next? Five Things To Look Out For In May

 
• By Dean Rudge

Generics Bulletin previews the most noteworthy and anticipated events for May 2025.

Sandoz And Henlius Join Forces With $300m Ipilimumab Deal

 
• By Dave Wallace

Sandoz has struck a deal worth up to $301m with Henlius giving it rights to a proposed ipilimumab biosimilar to Yervoy in countries across the world.

Speranza Starts Generics Offshoot In Response To Wider US Pharma Manufacturing Drive

 
• By Adam Zamecnik

Reflecting increased regulatory pressure and a wider drive towards the reshoring of pharmaceutical manufacturing to the US, Speranza has launched a new generics business called Lotus Therapeutics.